Red blood cell concentrates treated with the amustaline (S‐303) pathogen reduction system and stored for 35 days retain post‐transfusion viability: results of a two‐centre study

José A. Cancelas, Jerome L. Gottschall, Neeta Rugg, +8

Vox Sanguinis

Red blood cells treated with the amustaline (S‐303) pathogen reduction system: a transfusion study in cardiac surgery

V. Brixner, Katharina Madlener, Markus Müller, +16

Transfusion

Five-Day Changes in Biomarkers of Exposure Among Adult Smokers After Completely Switching From Combustible Cigarettes to a Nicotine-Salt Pod System

J. Bennett Jay, Erika L. Pfaunmiller, Norman Huang, +2

Nicotine & Tobacco Research

DRAVET ENGAGE. Parent caregivers of children with Dravet syndrome: Perspectives, needs, and opportunities for clinical research

Clara Juandó‐Prats, Emma S. James, Deborah A. Bilder, +8

Epilepsy & Behavior

Amustaline‐glutathione pathogen‐reduced red blood cell concentrates for transfusion‐dependent thalassaemia

Yeşim Aydınok, Antonio Piga, Raffaella Origa, +9

British Journal of Haematology

Transfusion of pathogen‐reduced platelet components without leukoreduction

Joycelyn Sim, Wai Chiu Tsoi, Cheuk Kwong Lee, +10

Transfusion

Severe communication delays are independent of seizure burden and persist despite contemporary treatments in <i>SCN1A</i>+ Dravet syndrome: Insights from the <scp>ENVISION</scp> natural history study

Μ. Scott Perry, Ingrid E. Scheffer, Joseph Sullivan, +26

Epilepsia

Comparative effectiveness of plasma prepared with amotosalen‐UVA pathogen inactivation and conventional plasma for support of liver transplantation

J Cinqualbre, Daniel Kientz, Emilie Remy, +3

Transfusion

Plasma treated with amotosalen and ultraviolet <scp>A</scp> light retains activity for hemostasis after 5 days post‐thaw storage at 1 to 6^o<scp>C</scp>

Anna Erickson, Katie Waldhaus, Tovo David, +5

Transfusion